【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 3800次   下载 3005 本文二维码信息
码上扫一扫!
罗格列酮对2型糖尿病患者外周血单核细胞CD36表达的影响
徐茂锦1,赵琳1,韩巧君1,张军2,邹大进1*
0
(1.第二军医大学长海医院内分泌科,上海 200433;2.第二军医大学长海医院实验诊断科,上海 200433)
摘要:
目的:观察2型糖尿病患者外周血单核细胞CD36的表达及罗格列酮对其表达的影响,探讨其可能的作用机制。方法:采用流式细胞仪测定2型糖尿病患者外周血单核细胞CD36的表达,并观察罗格列酮治疗后的变化;分析CD36与2型糖尿病各临床指标间的关系。结果:2型糖尿病组患者单核细胞CD36表达明显高于正常对照组(745.9±281.3 vs 406.3±80.2,P<0.01);动脉粥样硬化组CD36表达明显高于无动脉粥样硬化组(878.2±296.1 vs 584.2±148.3,P<0.01)。罗格列酮治疗后,患者单核细胞CD36表达、空腹血糖(FBG)、餐后血糖(PBG)、HbA1c、空腹胰岛素(FIN)、餐后胰岛素(PIN)、胰岛素抵抗程度(HOMA-IR)均降低,与治疗前、安慰剂组均有统计学差异(P<0.05或P<0.01)。糖尿病患者单核细胞CD36表达与FBG(r=0.55,P<0.05)、HbA1c(r=0.62,P<0.01)、HOMA-IR(r=0.64,P<0.01)正相关,与PBG、FIN、PIN无明显相关。结论:罗格列酮可能通过有效控制血糖、降低胰岛素抵抗等途径来降低2型糖尿病患者外周血单核细胞CD36的表达。
关键词:  CD36  2型糖尿病  单核细胞  动脉粥样硬化  罗格列酮
DOI:10.3724/SP.J.1008.2009.0409
投稿时间:2008-03-07修订日期:2009-03-10
基金项目:
Effect of rosiglitazone on expression of CD36 in peripheral monocytes in patients with Type 2 diabetes
XU Mao-jin1,ZHAO Lin1,HAN Qiao-jun1,ZHANG Jun2,ZOU Da-jin1*
(1. Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;2. Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433)
Abstract:
Objective:To observe the expression of CD36 in peripheral monocytes in patients with Type 2 diabetes, and to study the influence of rosiglitazone on CD36 expression and the related the mechanism. Methods: The expression of CD36 in the peripheral monocytes of patients with Type 2 diabetes was measured by flow cytometry before and after rosiglitazone treatment; the correlation between monocytes CD36 expression and metabolic index was analyzed. Results: Flow cytometry showed that the mean fluorescence intensity (MFI ) of monocyte CD36 in Type 2 diabetes was significantly higher than that in the healthy controls(745.9±281.3 vs 406.3±80.2,P<0.01). CD36 MFI in patients with Type 2 diabetes atherosclerosis was significantly higher than that in patients with Type 2 diabetes non-atherosclerosis(878.2±296.1 vs 584.2±148.3,P<0.01). Besides, we also found that CD36 expression, fasting blood glucose(FBG), post-prandial blood glucose(PBG), hemoglobin A1c(HbA1c), FIN, PIN, and HOMA-IR were all significantly decreased after rosiglitazone intervention compared with those before rosiglitazone intervetion and placebo group(P<0.05 or P<0.01). There was a positive correlation between monocyte CD36 expression with FBG(r=0.55,P<0.05), HbA1c(r=0.62,P<0.01), and HOMA-IR(r=0.64,P<0.01); but the expression was not correlated with PBG, FIN, or PIN. Conclusion: The increased expression of CD36 in monocytes of patients with Type 2 diabetes may be one of the mechanisms for accelerated atherosclerosis in diabetic patients. Rosiglitazone can decrease CD36 expression in monocytes through effectively controlling the blood glucose and decreasing insulin resistance.
Key words:  CD36  type 2 diabetes mellitus  monocytes  atherosclerosis  rosiglitazone